Thank you Sam!
All - my assistant Austin and I are collecting issues and comments from
contributors as github issues on the Community Group Note repo
(https://github.com/w3c/hcls-drug-drug-interaction/issues).
*The commenting period ends on May 17th. *
I plan to send doodle poll out shortly for an 'all team' meeting in the
beginning of June to report on how we addressed straightforward issues
and discuss issues that require consensus to address (such as Sam's
comment about changing the human readable labels for the the MPIO
concepts 'seriousness' and 'severity') .
Keep the comments coming!
best,
-Rich
On 04/30/2018 03:38 PM, Sam Habiel wrote:
> I read the rest of the document, and overall I am very impressed. It's
> very good. There are some minor comments:
>
> - PDF should have page numbers. I found it difficult to navigate it
> when printed.
> - In the appendix, it's possible to specify an ingredient level entity
> in RxNorm (or Clinical Dose Form Group) to avoid having to specify
> every single drug.
> - In the straw man XMLs, besides my comment regarding the MPIO tags,
> if you have references section, they should be all together in a
> single tag, b/c they are usually shared. We shouldn't have references
> for each section.
> - There is a stray ">>>> master" near the end of the document.
>
> --Sam
>
> On Mon, Apr 30, 2018 at 10:51 AM, Sam Habiel <sam.habiel@gmail.com
> <mailto:sam.habiel@gmail.com>> wrote:
>
> Rich,
>
> I didn't finish the document yet, but there were two issues that I
> previously raised that were not addressed:
>
> I do not think Seriousness and Severity are semantically different
> to readers. I would rather you use "Morbidity" and "Reaction
> Intensity" for these terms. At least I can sorta tell these apart.
>
> I would rather the sample XML use tags that do not include colons
> and are semantically meaningful. <interaction></interaction>
> rather than <MPIO:1111000>, which is meaningless to me.
>
>
> --Sam
>
>
> On Thu, Apr 26, 2018 at 11:15 AM, Richard Boyce <rdb20@pitt.edu
> <mailto:rdb20@pitt.edu>> wrote:
>
> Dear Task Force Colleagues,
>
> I am pleased to announce that we have completed major revision
> on the draft community group note on the topic of a potential
> drug-drug interaction (PDDI) minimum information model. The
> content of the note is not very different from prior versions
> but the organization and format is considerably changed with
> the goal of making it a much more usable report for a
> technical audience.
>
> I have checked with the other editors on this note and have
> received very positive feedback. I am asking all contributors
> for any final feedback before we officially publish as W3C
> Community Group Note.
>
> You can view the note here:
>
> - Temporary web location (what the note will ultimately look
> like):
> https://dbmi-icode-01.dbmi.pitt.edu/dikb-evidence/hcls-drug-drug-interaction/index.html
> <https://na01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fdbmi-icode-01.dbmi.pitt.edu%2Fdikb-evidence%2Fhcls-drug-drug-interaction%2Findex.html&data=01%7C01%7Crdb20%40pitt.edu%7C2058a6c4fead45112a9808d5aed20669%7C9ef9f489e0a04eeb87cc3a526112fd0d%7C1&sdata=Tf94mjHjPLz%2B3UHnszdZWwepMHozSzfSNFhP1tmlTgs%3D&reserved=0>
>
>
> - Word and PDF versions in case you want to make
> edits/comments (please note that the final version of this
> will be rendered as shown on the web version)
>
> Please reply directly to me or on the Community Group mailing
> list (public-hclscg@w3.org <mailto:public-hclscg@w3.org>) with
> any comments, edits, or concerns within three weeks (by May
> 17th). Please ensure that your name and affiliation is written
> correctly. Also, an funding acknowledgement that needs mentioned.
>
> thanks a bunch!
>
> -Rich
>
> --
> Richard D Boyce, PhD
> Associate Professor of Biomedical Informatics and Clinical and
> Translational Science in the Clinical and Translational
> Science Institute
> Director of the Informatics Core for the Center of Excellence
> for Natural Product- Drug Interaction Research (NaPDI)
> Faculty, Center for Pharmaceutical Policy and Prescribing
> Faculty, Geriatric Pharmaceutical Outcomes and
> Gero-Informatics Research and Training Program
> University of Pittsburgh
> rdb20@pitt.edu <mailto:rdb20@pitt.edu>
> Office: 412-648-9219
> Twitter: @bhaapgh
>
>
>
--
Richard D Boyce, PhD
Associate Professor of Biomedical Informatics and Clinical and Translational Science in the Clinical and Translational
Science Institute
Director of the Informatics Core for the Center of Excellence for Natural Product- Drug Interaction Research (NaPDI)
Faculty, Center for Pharmaceutical Policy and Prescribing
Faculty, Geriatric Pharmaceutical Outcomes and Gero-Informatics Research and Training Program
University of Pittsburgh
rdb20@pitt.edu
Office: 412-648-9219
Twitter: @bhaapgh